The invention relates to SOCS1 derived isolated polypeptides and compositions comprising such polypeptides for use in the prevention, relief and/or treatment of an overweight/obesity and diabetes related liver disorder or a pathological condition or disease caused by fatty liver, specifically non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) or metabolic associated fatty liver disease (MAFLD).
1. An isolated polypeptide comprising a) the sequence of SEQ ID NO.1 or SEQ ID NO.2; or b) a variant of any of the sequences of a) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical SEQ ID NO.1 or SEQ ID NO.2, respectively, for use in the prevention, relief and/or treatment of an overweight related or obesity related liver disorder or a pathological condition or disease caused by fatty liver, specifically non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) or metabolic associated fatty liver disease (MAFLD). 2. The polypeptide for use according to claim 1, wherein the isolated polypeptide further comprises at least one of the following amino acid substitutions based on the amino acid sequence of SEQ ID NO.1: H3C(Acm), F4R, R5Q, F7Nal1, S9K, A11S, a deletion of amino acids A11 to 116, or a combination thereof. 3. The polypeptide for use according to claims 1 or 2, wherein the isolated polypeptide comprises a) the sequence of any of SEQ IN NO.3 or SEQ ID NO.4; or b) a variant of any of the sequences of a) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO.3 or SEQ ID NO.4, respectively. 4. The polypeptide for use according to claims 1 to 3, wherein the pathological condition or disease is an overweight related or an obesity related liver disorder selected from steatosis, steatohepatitis, liver fibrosis or cirrhosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic associated fatty liver disease (MAFLD) and NAFLD related cirrhosis. 5. The polypeptide for use according to any one of claims 1 to 4, wherein the polypeptide consists of i. the amino acid sequence of SEQ ID NO.1; or ii. the amino acid sequence of SEQ ID NO.2; or iii. the amino acid sequence of SEQ ID NO.3; or iv. the amino acid sequence of SEQ ID NO.4. 6. The polypeptide for use according to any one of claims 1 to 5, consisting of a) the murine SOCS1 protein (UniProt: 035716); b) the human SOCS1 protein (UniProt: 015524); or c) a variant of the sequence of a) or b) which is at least 80% homologous to the amino acid sequence of the murine SOCS1 protein or to the amino acid sequence of the human SOCS1 protein. 7. The polypeptide for use according to any one of claims 1 to 6, consisting of the sequence SEQ ID NO.1, SEQ ID NO.2, SEQ IN NO.3 or SEQ ID NO.4, wherein the polypeptide is bound to a cell permeability region. 8. A polypeptide for use according to any one of claims 1 to 7, wherein at least one amino acid of the sequence thereof is phosphorylated, preferably wherein at least one of the phosphorylated amino acids is a tyrosine (Y). 9. A composition, preferably a pharmaceutical composition, comprising a therapeutically effective amount of a polypeptide as defined in any one of claims 1 to 8, and at least one pharmaceutically acceptable vehicle or excipient, for use in the prevention, relief and/or treatment of an obesity related liver disorder or a pathological condition or disease caused by fatty liver, preferably wherein the pathological condition or disease caused by fatty liver is selected from steatosis, steatohepatitis, liver fibrosis or cirrhosis, more preferably non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and NAFLD related cirrhosis. 10. The composition for use according to claim 9, wherein the composition further comprises another active ingredient, preferably selected from vitamin E, semaglutide, tirzepatide, empaglifozin and losartan. 11. The composition for use according to claims 9 or 10, wherein the composition further comprises a pharmaceutically acceptable excipient. 12. The composition for use according to any one of claims 9 to 11, wherein said composition is suitable for oral, gastroenteric, parenteral, or rectal administration, preferably parenteral administration.